User profiles for "author:Ruben Smith"

Ruben Smith

Lund University
Verified email at med.lu.se
Cited by 9300

The pregnancy risk assessment monitoring system (PRAMS): overview of design and methodology

HB Shulman, DV D'Angelo… - … journal of public …, 2018 - ajph.aphapublications.org
Data System. The Pregnancy Risk Assessment Monitoring System (PRAMS) is an ongoing
state-based surveillance system of maternal behaviors, attitudes, and experiences before …

Synaptic dysfunction in Huntington's disease: a new perspective

R Smith, P Brundin, JY Li - Cellular and Molecular Life Sciences CMLS, 2005 - Springer
Huntington's disease (HD) is caused by a polyglutamine expansion in the protein huntingtin
and is characterized by intraneuronal inclusions and widespread neuronal death at the late …

Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders

S Palmqvist, S Janelidze, YT Quiroz, H Zetterberg… - Jama, 2020 - jamanetwork.com
Importance There are limitations in current diagnostic testing approaches for Alzheimer
disease (AD). Objective To examine plasma tau phosphorylated at threonine 217 (P-tau217) …

Four distinct trajectories of tau deposition identified in Alzheimer's disease

JW Vogel, AL Young, NP Oxtoby, R Smith… - Nature medicine, 2021 - nature.com
Alzheimer's disease (AD) is characterized by the spread of tau pathology throughout the
cerebral cortex. This spreading pattern was thought to be fairly consistent across individuals …

Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia

S Janelidze, N Mattsson, S Palmqvist, R Smith… - Nature medicine, 2020 - nature.com
Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer's disease (AD),
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P …

[HTML][HTML] Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

R Ossenkoppele, A Pichet Binette, C Groot, R Smith… - Nature medicine, 2022 - nature.com
A major unanswered question in the dementia field is whether cognitively unimpaired
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease

JB Pereira, S Janelidze, R Smith, N Mattsson-Carlgren… - Brain, 2021 - academic.oup.com
Although recent clinical trials targeting amyloid-β in Alzheimer's disease have shown
promising results, there is increasing evidence suggesting that understanding alternative …

Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid …

R Ossenkoppele, R Smith, N Mattsson-Carlgren… - JAMA …, 2021 - jamanetwork.com
Importance Tau positron emission tomography (PET) tracers have proven useful for the
differential diagnosis of dementia, but their utility for predicting cognitive change is unclear …

Discriminative accuracy of [18F] flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders

R Ossenkoppele, GD Rabinovici, R Smith, H Cho… - Jama, 2018 - jamanetwork.com
Importance The positron emission tomography (PET) tracer [18 F] flortaucipir allows in vivo
quantification of paired helical filament tau, a core neuropathological feature of Alzheimer …

Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease

S Janelidze, D Berron, R Smith, O Strandberg… - JAMA …, 2021 - jamanetwork.com
Importance There is an urgent need for inexpensive and minimally invasive blood
biomarkers for Alzheimer disease (AD) that could be used to detect early disease changes …